1 型糖尿病的免疫疗法：我们在哪里，我们应该去哪里？
Immunotherapy of type 1 diabetes: where are we and where should we be going?
机构信息
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
出版信息
Immunity. 2010 Apr 23;32(4):488-99. doi: 10.1016/j.immuni.2010.04.002.
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic beta cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by "tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing beta cells from endogenous progenitors.
摘要
1 型糖尿病（T1D）是一种慢性自身免疫性疾病，其特征是破坏产生胰岛素的胰腺β细胞。目前已经有许多基于广泛的免疫抑制和抗原特异性免疫调节治疗方法正在被评估其在预防和治疗 T1D 中的效用。展望未来，本文讨论了抗原特异性耐受策略的潜在治疗用途，包括用致糖尿病抗原脉冲处理的“耐受性”抗原呈递细胞诱导的耐受和诱导或扩增的调节性 T 细胞的转移，这些方法在非肥胖糖尿病（NOD）小鼠中已证明有效。根据 T1D 病程中治疗干预的时间，抗原特异性免疫调节策略可以作为单一疗法，或与短期促进耐受的免疫调节药物和/或促进内源性祖细胞产生胰岛素的β细胞分化的药物联合使用。
相似文献
1
Immunotherapy of type 1 diabetes: where are we and where should we be going?1 型糖尿病的免疫疗法：我们在哪里，我们应该去哪里？
Immunity. 2010 Apr 23;32(4):488-99. doi: 10.1016/j.immuni.2010.04.002.
2
APC-targeted proinsulin expression inactivates insulin-specific memory CD8 T cells in NOD mice.APC 靶向的胰岛素原表达使 NOD 小鼠的胰岛素特异性记忆 CD8 T 细胞失活。
Immunol Cell Biol. 2017 Oct;95(9):765-774. doi: 10.1038/icb.2017.48. Epub 2017 Jun 14.
3
Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes.谷氨酸脱羧酶致耐受性肽作为1型糖尿病抗原特异性免疫治疗候选物的临床前开发。
Diabetes. 2025 Mar 1;74(3):384-397. doi: 10.2337/db23-0996.
4
Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.针对 1 型糖尿病的自身免疫及胰岛β细胞功能障碍的个体化细胞治疗选择：现有方案及未来展望。
Adv Exp Med Biol. 2010;654:641-65. doi: 10.1007/978-90-481-3271-3_28.
5
Antigen presenting cell-targeted proinsulin expression converts insulin-specific CD8 T-cell priming to tolerance in autoimmune-prone NOD mice.抗原呈递细胞靶向性胰岛素原表达可将自身免疫易感的非肥胖糖尿病（NOD）小鼠中胰岛素特异性CD8 T细胞的致敏转化为耐受。
Eur J Immunol. 2017 Sep;47(9):1550-1561. doi: 10.1002/eji.201747089. Epub 2017 Jul 18.
6
The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes.信号调节蛋白家族和 CD47 信号通路在 1 型糖尿病中的免疫调节作用。
Front Immunol. 2021 Sep 16;12:739048. doi: 10.3389/fimmu.2021.739048. eCollection 2021.
7
Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice.包载多种重组胰岛β细胞蛋白的免疫耐受调节纳米颗粒可预防非肥胖型糖尿病小鼠 1 型糖尿病的发生和进展。
J Immunol. 2022 Aug 1;209(3):465-475. doi: 10.4049/jimmunol.2200208. Epub 2022 Jun 20.
8
Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.新生非肥胖糖尿病（NOD）小鼠中天然存在的CD4+CD25+调节性T淋巴细胞对1型自身免疫性糖尿病的控制
Ann N Y Acad Sci. 2005 Jun;1051:72-87. doi: 10.1196/annals.1361.048.
9
Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies.非耗竭性抗 CD4 和抗 CD8 抗体可诱导 NOD 小鼠的糖尿病长期缓解。
Diabetes. 2012 Nov;61(11):2871-80. doi: 10.2337/db12-0098. Epub 2012 Jun 29.
10
Tetrahedral Framework Nucleic Acids Reverse New-Onset Type 1 Diabetes.四面体框架核酸逆转新诊断 1 型糖尿病。
ACS Appl Mater Interfaces. 2021 Nov 3;13(43):50802-50811. doi: 10.1021/acsami.1c16151. Epub 2021 Oct 19.
引用本文的文献
1
Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review.抗胸腺细胞球蛋白在1型糖尿病中的治疗潜力：一项系统评价。
PLoS One. 2025 May 13;20(5):e0323642. doi: 10.1371/journal.pone.0323642. eCollection 2025.
2
Mechanism of Action of Oral -Based Vaccine to Prevent and Reverse Type 1 Diabetes in NOD Mice.口服疫苗预防和逆转非肥胖糖尿病（NOD）小鼠1型糖尿病的作用机制
Vaccines (Basel). 2024 Mar 6;12(3):276. doi: 10.3390/vaccines12030276.
3
TYK2 signaling promotes the development of autoreactive CD8 cytotoxic T lymphocytes and type 1 diabetes.TYK2 信号通路促进自身反应性 CD8 细胞毒性 T 淋巴细胞和 1 型糖尿病的发生。
Nat Commun. 2024 Feb 13;15(1):1337. doi: 10.1038/s41467-024-45573-9.
4
Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance.用于诱导免疫耐受的肝脏靶向纳米平台
Nanomaterials (Basel). 2023 Dec 26;14(1):67. doi: 10.3390/nano14010067.
5
Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation.通过生物材料介导的免疫调节实现胰岛免疫耐受的理性工程化。
J Immunol. 2024 Jan 15;212(2):216-224. doi: 10.4049/jimmunol.2300527.
6
Magnetic Particle Imaging of Transplanted Human Islets Using a Machine Learning Algorithm.基于机器学习算法的移植人胰岛的磁粒子成像。
Methods Mol Biol. 2023;2592:185-194. doi: 10.1007/978-1-0716-2807-2_13.
7
Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice.包载多种重组胰岛β细胞蛋白的免疫耐受调节纳米颗粒可预防非肥胖型糖尿病小鼠 1 型糖尿病的发生和进展。
J Immunol. 2022 Aug 1;209(3):465-475. doi: 10.4049/jimmunol.2200208. Epub 2022 Jun 20.
8
Enhancing Antigen Presentation and Inducing Antigen-Specific Immune Tolerance with Amphiphilic Peptides.两亲性肽增强抗原呈递和诱导抗原特异性免疫耐受。
J Immunol. 2021 Oct 15;207(8):2051-2059. doi: 10.4049/jimmunol.1901301. Epub 2021 Sep 15.
9
Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.新兴的治疗策略，以恢复 1 型糖尿病中胰岛自身免疫的调节性 T 细胞控制。
Front Immunol. 2021 Mar 18;12:635767. doi: 10.3389/fimmu.2021.635767. eCollection 2021.
10
Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.1 型糖尿病免疫治疗的现状。
Curr Diab Rep. 2019 Mar 23;19(5):22. doi: 10.1007/s11892-019-1144-3.
本文引用的文献
1
Dimorphic histopathology of long-standing childhood-onset diabetes.长期儿童起病糖尿病的二态组织病理学。
Diabetologia. 2010 Apr;53(4):690-8. doi: 10.1007/s00125-009-1642-y. Epub 2010 Jan 9.
2
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.利妥昔单抗、B淋巴细胞清除与β细胞功能的保留
N Engl J Med. 2009 Nov 26;361(22):2143-52. doi: 10.1056/NEJMoa0904452.
3
Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.胰岛素 B 链免疫疗法诱导 1 型糖尿病患者自身抗原特异性调节性 T 细胞。
J Autoimmun. 2010 Jun;34(4):408-15. doi: 10.1016/j.jaut.2009.10.005.
4
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.程序性死亡受体1（PD-1）与程序性死亡配体1（PD-L1）之间的相互作用通过阻断T细胞受体（TCR）诱导的终止信号来促进免疫耐受。
Nat Immunol. 2009 Nov;10(11):1185-92. doi: 10.1038/ni.1790. Epub 2009 Sep 27.
5
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes.胰岛自身反应性 T 细胞检测在早期 1 型糖尿病患者中的测量的有效性和可重复性。
Diabetes. 2009 Nov;58(11):2588-95. doi: 10.2337/db09-0249. Epub 2009 Aug 12.
6
Diabetes: A virus-gene collaboration.糖尿病：病毒与基因的协同作用。
Nature. 2009 May 28;459(7246):518-9. doi: 10.1038/459518a.
7
Genetics of type 1A diabetes.1A型糖尿病的遗传学
N Engl J Med. 2009 Apr 16;360(16):1646-54. doi: 10.1056/NEJMra0808284.
8
Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.依那西普治疗新诊断1型糖尿病儿童：随机、安慰剂对照、双盲试验性研究
Diabetes Care. 2009 Jul;32(7):1244-9. doi: 10.2337/dc09-0054. Epub 2009 Apr 14.
9
C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.初诊1型糖尿病患者自体非清髓性造血干细胞移植后的C肽水平与胰岛素非依赖状态
JAMA. 2009 Apr 15;301(15):1573-9. doi: 10.1001/jama.2009.470.
10
Genetic and therapeutic control of diabetogenic CD8+ T cells.致糖尿病性CD8 + T细胞的基因与治疗性控制
Novartis Found Symp. 2008;292:130-6; discussion 136-45, 202-3. doi: 10.1002/9780470697405.ch12.
Zotero 插件